This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PolyMedix Defensin-Mimetic Anti-Malaria Data Published In Cell Host And Microbe

RADNOR, Pa., Jan. 14, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company dedicated to developing novel treatments for infectious diseases with defensin-mimetic antimicrobial agents, today announced that pre-clinical data demonstrating activity of the Company's defensin-mimetic antimicrobial compounds against the parasite that causes malaria, Plasmodium falciparum, were published in the December issue of Cell Host and Microbe, a peer-reviewed scientific journal.

The article entitled, " Platelet Factor 4 Activity against P. falciparum and Its Translation to Nonpeptidic Mimics as Antimalarials" is the result of a collaboration between PolyMedix and the University of Pennsylvania, Drexel University and John Hopkins University.

PolyMedix's library of defensin-mimetic antimicrobial compounds were screened to identify those capable of selectively killing the P. falciparum parasite without showing signs of cytotoxicity toward mammalian cells. A number of PolyMedix's defensin-mimetic compounds showed a high degree of activity against both drug-sensitive and drug–resistant parasites and act in a similar fashion to human platelet factor 4 (hPF4), a naturally-occurring protein. hPF4 is produced by platelets and has been observed to kill the malaria parasite in infected red cells without harming the red cell itself. The defensin-mimetic compounds and hPF4 appear to act via the same unique mechanism, which is distinct from other anti-malarial agents, by rapidly destroying the digestive vacuole of the parasite essentially starving it of food and releasing digestive enzymes. Furthermore, in the study, the mimetic compounds acted with greater speed and potency than the natural hPF4 protein, suggesting an advantage of the PolyMedix protein-mimetic approach.

Two of the lead defensin-mimetic compounds were tested in mouse models of malaria. Both compounds significantly decreased parasitic growth and greatly improved survival rates, providing further confirmation of the potential of defensin-mimetics as antimalarial agents.

"Our work shows that it may be possible to mimic a natural mechanism of the innate immune system with drug-like small molecules that we believe could be optimized to create potent, selective, potentially less toxic, and cheaper to make antimalarials," commented Dr. Doron Greenbaum, assistant professor of pharmacology at the Perelman School of Medicine, University of Pennsylvania. "Targeting parasite membranes rather than proteins using PolyMedix's defensin-mimetics represents a highly innovative and novel approach for treating parasitic diseases." 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs